Related Articles
IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets
Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours
Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.